Pharmacotherapy for adolescent alcohol use disorder

CNS Drugs

Volumn 26, Issue 7, 2012, Pages 559-569

  Clark, Duncan B ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Acamprosate; Adolescents; Alcohol; Alcohol related disorders; Alcohol use; Alcohol withdrawal; Attention deficit hyperactivity disorder; Benzodiazepines; Disulfiram; Major depressive disorder; Naltrexone; Substance related disorders

Indexed keywords

ACAMPROSATE; AMFEBUTAMONE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATOMOXETINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORDIAZEPOXIDE; CLONIDINE; DIAZEPAM; DISULFIRAM; FLUOXETINE; METHYLPHENIDATE; NALMEFENE; NALTREXONE; ONDANSETRON; PLACEBO; PSYCHOSTIMULANT AGENT; QUETIAPINE; TOPIRAMATE;

ADOLESCENT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL METABOLISM; ALCOHOL USE DISORDER; ALCOHOL WITHDRAWAL; ALCOHOLISM; ATTENTION DEFICIT DISORDER; AVERSION THERAPY; BIPOLAR DISORDER; BORDERLINE STATE; CHILD DEVELOPMENT; CHILD PSYCHIATRY; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG DEPENDENCE TREATMENT; DRUG MEGADOSE; DSM-IV; HUMAN; LIVER INJURY; LIVER TOXICITY; MAJOR DEPRESSION; MOTIVATION; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT MONITORING; PATIENT SELECTION; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSIS; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REINFORCEMENT; REVIEW;

ADOLESCENT; ALCOHOL-RELATED DISORDERS; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BENZODIAZEPINES; CENTRAL NERVOUS SYSTEM STIMULANTS; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISULFIRAM; HUMANS; NALTREXONE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; TAURINE;

EID: 84862571620     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11634330-000000000-00000     Document Type: Review

References (72)

1. Thatcher DL, Clark DB. Adolescent alcohol abuse and dependence: development, diagnosis, treatment and outcomes. Curr Psychiatry Rev 2006; 2: 159-77 (Pubitemid 44027875)
2. Chung T, Martin CS. Prevalence and clinical course of adolescent substance use and substance use disorders. In: Kaminer Y, Winters KC, editors. Clinical manual of adolescent substance abuse treatment. Washington, DC: American Psychiatric Publishing, 2011: 1-23
3. Brown SA, McGue M, Maggs J, et al. A developmental perspective on alcohol and youths 16 to 20 years of age. Pediatrics 2008; 121 Suppl. 4: s290-310
4. Tripodi SJ, Bender K, Litschge C, et al. Interventions for reducing adolescent alcohol abuse. Arch Pediatr Adolesc Med 2010; 164 (1): 85-91
5. Maisto SA, Chung T, Martin CS, et al. A comparison of the concurrent and predictive validity of four measures of readiness to change alcohol use in a clinical sample of adolescents. Psychol Assess 2001; 23 (4): 983-94
6. Martin CS, Chung T, Langenbucher JW. How should we revise diagnostic criteria for substance use disorders in the DSM-V? J Abnorm Psychol 2008; 117: 561-75
7. Langenbucher J, Martin C, Labouvie E, et al. Toward the DSM-V: a withdrawal-gate model of alcohol abuse and dependence. J Consult Clin Psychol 2000; 68: 799-809
8. Martin CS, Langenbucher JW, Kaczynski NA, et al. Staging in the onset of DSM-IV alcohol symptoms in adolescents: survival/hazard analyses. J Stud Alcohol 1996; 57: 549-58 (Pubitemid 26268771)
9. Martin CS, Kaczynski NA, Maisto SA, et al. Patterns of DSM-IV alcohol abuse and dependence symptoms in adolescent drinkers. J Stud Alcohol 1995; 56 (6): 672-80
10. Clark DB, Kirisci L, Tarter RE. Adolescent versus adult onset and the development of substance use disorders in males. Drug Alcohol Depend 1998; 49: 115-21 (Pubitemid 28111898)
11. Deas D, Riggs P, Langenbucher J, et al. Adolescents are not adults: developmental considerations in alcohol users. Alcohol Clin Exp Res 2000; 24 (2): 232-7 (Pubitemid 30117427)
12. Chung T, Martin CS, Winters KC, et al. Assessment of alcohol tolerance in adolescents. J Stud Alcohol 2001; 62: 687-95 (Pubitemid 33021408)
13. Chung T, Martin CS. What were they thinking? Adolescents'interpretations of DSM-IV alcohol dependence symptom queries and implications for diagnostic validity. Drug Alcohol Depend 2005; 80: 191-200 (Pubitemid 41427633)
14. American Psychiatric Association. DSM-5: the future of psychiatric diagnosis [online]. Available from URL: http://www.dsm5.org [Accessed 2012 May 17]
15. Johnston LD, O'Malley PM, Bachman JG, et al. Monitoring the future national results on adolescent drug use: overview of key findings, 2011 [online]. Ann Arbor (MI): Institute for Social Research, The University of Michigan. Available from URL: http://www.monitoringthefuture.org [Accessed 2012 May 17]
16. Kaminer Y, Goldberg P, Connor DF. Psychotropic medications and substances of abuse interactions in youth. Subst Abus 2010; 31: 53-7
17. Clark DB, Pollock NA, Bromberger JT, et al. Gender and comorbid psychopathology in adolescents with alcohol use disorders. J Am Acad Child Adolesc Psychiatry 1997; 36 (9): 1195-203 (Pubitemid 27381275)
18. Clark DB, Lesnick L, Hegedus A. Trauma and other stressors in adolescent alcohol dependence and abuse. J Am Acad Child Adolesc Psychiatry 1997; 36 (12): 1744-51 (Pubitemid 27512329)
19. Clark DB, Thatcher DL, Martin CS. Child abuse and other traumatic experiences, alcohol use disorders, and health problems in adolescence and young adulthood. J Pediatr Psychol 2010; 35 (5): 499-510
20. Cornelius JR, Maisto SA, Martin CS, et al. Major depression associated with earlier alcohol relapse in treated teens with AUD. Addict Behav 2004; 29: 1035-8 (Pubitemid 38822965)
21. Aarons GA, Brown SA, CoeMT, et al. Adolescent alcohol and drug abuse and health. J Adolesc Health 1997; 24: 412-21
22. Hansell S, White HR, Vali FM. Specific alcoholic beverages and physical and mental health among adolescents. J Stud Alcohol 1999; 60: 209-18 (Pubitemid 29091603)
23. Clark DB, Lynch KG, Donovan JD, et al. Health problems in adolescents with alcohol use disorders: self-report, liver injury and physical examination findings. Alcohol Clin Exp Res 2001; 25: 1350-9 (Pubitemid 32868345)
24. Clark DB. The natural history of adolescent alcohol use disorders. Addiction 2004; 99 Suppl. 2: 5-22 (Pubitemid 39490507)
25. Rohde P, Lewinsohn PM, Kahler CW, et al. Natural course of alcohol use disorders from adolescence to young adulthood. J Am Acad Child Adolesc Psychiatry 2001; 40 (1): 83-90 (Pubitemid 32047232)
26. Simkin DR, Grenoble S. Pharmacotherapies for adolescent substance use disorders. Child Adolesc Psychiatric Clin N Am 2010; 19: 591-608
27. Chang PH, Steinberg MB. Alcohol withdrawal. Med Clin N Am 2001; 85 (5): 1191-212 (Pubitemid 32862137)
28. Campos J, Roca L, Gude F, et al. Long-term mortality of patients admitted to the hospital with alcohol withdrawal syndrome. Alcohol Clin Exp Res 2011; 35(6): 1180-6
29. Brown SA, Tapert SF, Granholm E, et al. Neurocognitive functioning of adolescents: effects of protracted alcohol use. Alcohol Clin Exp Res 2000; 24: 164-71 (Pubitemid 30117417)
30. Chung T, Martin CS, Armstrong TD, et al. Prevalence of DSM-IV alcohol diagnoses and symptoms in adolescent community and clinical samples. J Am Acad Adolesc Psychiatry 2002; 41 (5): 546-54 (Pubitemid 38338133)
31. Craig M, Pennacchia A, Wright NR, et al. Evaluation of unmedicated, self-paced alcohol withdrawal. PLoS ONE 2011; 6 (7): e22994
32. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database Syst Rev 2011; (6): CD008537
33. Kaplan G, Ivanov I. Pharmacotherapy for substance abuse in adolescence. Pediatr Clin North Am 2011; 58: 243-58
34. Rolland B, Karila L, Guardia D, et al. Pharmacological approaches to binge drinking. Curr Pharm Des 2011; 17: 1333-42
35. Ilomaki R, Ilomaki E, Hakko H, et al. Psychotropic medication history of inpatient adolescents: is there a rationale for benzodiazepine prescription? Addict Behav 2011; 36: 161-5
36. Petrakis IL, Polling J, Levinson C, et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry 2005; 57 (10): 1128-37 (Pubitemid 40615774)
37. Suh JJ, Pettinati HM, Kampman KM, et al. The status of disulfiram: a half century later. J Clin Psychopharmacol 2006; 26 (3): 290-302 (Pubitemid 43804621)
38. Niederhofer H, Staffen W. Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents. Drug Alcohol Rev 2003; 22 (3): 295-7 (Pubitemid 37394836)
39. De Sousa A, De Sousa A. An open randomized trial comparing disulfiram and naltrexone in adolescents with alcohol dependence. J Subst Use 2008; 13 (6): 382-8
40. Myers WC, Donahue JE, Goldstein MR. Disulfiram for alcohol use disorders in adolescents. J Am Acad Child Adolesc Psychiatry 1994; 33: 484-9 (Pubitemid 24133067)
41. Garbutt JC. Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 2010; 16: 2091-7
42. Deas D, May K, Randall CL, et al. Naltrexone treatment of adolescent alcoholics: an open label pilot study. J Child Adolesc Psychopharmacol 2005; 15: 723-8 (Pubitemid 41567144)
43. Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56: 719-24 (Pubitemid 29357733)
44. Rösner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; (9): CD004332
45. Niederhofer H, Staffen W. Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry 2003; 12 (3): 144-8 (Pubitemid 36758682)
46. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 2003; 361 (9370): 1677-85 (Pubitemid 36577440)
47. Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for alcohol dependence. J Clin Psychopharmacol 2009; 29 (6): 584-9
48. Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000; 284 (8): 963-71 (Pubitemid 30659126)
49. Johnson BA, Ait-Doud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 2011; 168 (3): 265-75
50. Dawes MA, Johnson BA, Ait-Daoud N, et al.A prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav 2005; 30 (6): 1077-85 (Pubitemid 40745367)
51. Dawes MA, Johnson BA, Ma JZ, et al. Reductions in and relations between craving and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence. Addict Behav 2005; 30 (9): 1630-7 (Pubitemid 41443302)
52. Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119 (3): 276.e13-18
53. Addolorato G, Leggio L, Ferrulli A, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol 2011; 46 (3): 312-7
54. Clark DB, Wood DS, Cornelius JR, et al. Clinical practices in the pharmacological treatment of comorbid psychopathology in adolescents with alcohol use disorders. J Subst Abuse Treat 2003; 25: 293-5 (Pubitemid 38021935)
55. Cornelius JR, Bukstein OG, Wood DS, et al. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav 2009; 34: 905-9
56. Biederman J, Monuteaux MC, Spencer T, et al. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 2008; 165: 597-603 (Pubitemid 351705336)
57. Riggs PD, Winhusen T, Davies RD, et al. Randomized controlled trial of osmotic-release methylphenidate with cognitive behavior therapy in adolescents with attention deficit hyperactivity disorder and substance use disorders. J Am Acad Child Adolesc Psychiatry 2011; 50 (9): 903-14
58. Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallelgroup study. Clin Ther 2006; 28 (2): 266-79
59. Setlik J, Bond GR, Ho M. Adolescent prescription ADHD medication abuse is rising along with prescriptions for these medications. Pediatrics 2009; 124 (3): 875-80
60. Thurstone C, Riggs PD, Salononsen-Sautel S, et al. Randomized, controlled trial of atomoxetine for attention deficit hyperactivity disorder in adolescents with substance use disorder. J Am Acad Child Adolesc Psychiatry 2010; 49 (6): 573-82
61. Riggs PD, Leon SL, Mikulich SK, et al. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998; 37 (12): 1271-8 (Pubitemid 28550719)
62. Solhkhah R, Wilens TE, Daly J, et al. Bupropion SR for treatment of substance abusing outpatient adolescents with attention deficit hyperactivity disorder with mood disorders. J Child Adolesc Psychopharmacol 2005; 15 (5): 777-86 (Pubitemid 41567149)
63. Martinotti G, Andreoli S, Di Nicola M, et al. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol 2008; 23 (5): 417-24
64. Ray LA, Heydari A, Zorick T. Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. Drug Alcohol Rev 2010; 29: 568-75
65. Litten RZ, Fertig JB, Falk DE, et al. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res 2012 Mar; 36 (3): 406-16
66. Clark DB, Bukstein O, Cornelius J. Alcohol use disorders in adolescents: epidemiology, diagnosis, psychosocial interventions, and pharmacological treatment. Pediatr Drugs 2002; 4 (8): 493-502 (Pubitemid 34876155)
67. Cornelius JR, Bukstein O, Lynch K, et al. Fluoxetine in adolescents with major depression and an adolescent alcohol use disorder: an open label trial. Addict Behav 2001; 26: 735-9 (Pubitemid 32826211)
68. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry 2005; 44 (6): 609-11
69. Carroll KM, Kosten TR, Rounsaville BJ. Choosing a behavioral therapy platform for pharmacotherapy of substance users. Drug Alcohol Depend 2004; 75: 123-34 (Pubitemid 38970120)
70. Battjes RJ, Gordon MS, O'Grady KE, et al. Factors that predict adolescent motivation for substance abuse treatment. J Subst Abuse Treat 2003; 24 (3): 221-32 (Pubitemid 37297339)
71. Sullivan MA, Birkmayer F, Boyarsky BK, et al. Uses of coercion in addiction treatment: clinical aspects. Am J Addict 2008; 17 (1): 36-47 (Pubitemid 351157000)
72. Hall W, Capps B, Carter A. The use of depot naltrexone under legal coercion: the case for caution. Addiction 2008; 103 (12): 1922-4